Improving Metabolic and Cardiovascular Health at an Early Psychosis Intervention Program in Vancouver, Canada by Diane H. Fredrikson et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSYCHIATRY
METHODS ARTICLE
published: 05 September 2014
doi: 10.3389/fpsyt.2014.00105
Improving metabolic and cardiovascular health at an early
psychosis intervention program inVancouver, Canada
Diane H. Fredrikson1,2, Heidi N. Boyda1, LurdesTse1, ZacharyWhitney 1, Mark A. Pattison2, Fred J. Ott 2,
Laura Hansen2 and Alasdair M. Barr 1*
1 Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
2 Early Psychosis Intervention Program, Vancouver Coastal Health, Vancouver, BC, Canada
Edited by:
Jørn Heggelund, St. Olavs Hospital,
Trondheim University Hospital,
Norway
Reviewed by:
John Abel Engh, Vestfold Hospital
Trust, Norway
Gunnar Morken, Norwegian
University of Science andTechnology,
Norway
*Correspondence:
Alasdair M. Barr , Department of
Pharmacology, University of British
Columbia, 2176 Health Science Mall,
Vancouver, BC V6T 1Z3, Canada
e-mail: al.barr@ubc.ca
Psychotic disorders most commonly appear during the late teenage years and early adult-
hood. A focused and rapid clinical response by an integrated health team can help to
improve the quality of life of the patient, leading to a better long-term prognosis. The Van-
couver Coastal Health early psychosis intervention program covers a catchment area of
approximately 800,000 people in the cities of Vancouver and Richmond, Canada. The pro-
gram provides a multidisciplinary approach to supporting patients under the age of 30
who have recently experienced first-break psychosis. The program addresses the needs
of the treatment environment, medication, and psychological therapies. A critical part of
this support includes a program to specifically improve patients’ physical health. Physical
health needs are addressed through a two-pronged, parallel approach. Patients receive
routine metabolic health assessments during their first year in the program, where stan-
dard metabolic parameters are recorded. Based on the results of clinical interviews and
laboratory tests, specific actionable interventions are recommended.The second key strat-
egy is a program that promotes healthy lifestyle goal development. Patients work closely
with occupational therapists to develop goals to improve cardiometabolic health. These
programs are supported by an active research environment, where patients are able to
engage in studies with a focus on improving their physical health. These studies include
a longitudinal evaluation of the effects of integrated health coaching on maintaining car-
diometabolic health in patients recently admitted to the program, as well as a clinical study
that evaluates the effects of low versus higher metabolic risk antipsychotic drugs on central
adiposity. An additional pharmacogenomic study is helping to identify genetic variants that
may predict cardiometabolic changes following treatment with antipsychotic drugs.
Keywords: psychosis, antipsychotic, metabolic syndrome and diabetes mellitus, exercise, health coaching, mental
illness, schizophrenia
INTRODUCTION
The age of onset of schizophrenia spectrum disorders and most
other forms of idiopathic psychosis is typically during the later
teenage years through the early- to mid-20s. There is usually a
period of cognitive and functional decline prior to the first psy-
chotic break, which may be referred to as the “prodrome” (1). This
prodrome is characterized by changes from premorbid function-
ing that may be expressed in ways such as social withdrawal, loss
of employment, and decreased interest in academic or vocational
activities (2). The subsequent period associated with the initial
onset of overt psychotic symptoms represents a traumatic period
not only to the individual affected but also for family and friends
(3). This stress may be exacerbated by the lack of awareness among
the general population of the biological nature of psychotic disor-
ders, as well as the highly variable presentation of early psychotic
symptoms and the stigma associated with mental illness in general.
In recent years, there has been an increased awareness of the
need for programs that provide focused support specifically for
patients with a recently diagnosed psychotic disorder. The ratio-
nale for such “early psychosis intervention (EPI)” programs is
based in significant part on the biological hypothesis that dur-
ing the early stages of psychotic disorders, the brain’s plasticity
remains largely intact. Hence, optimal treatment with antipsy-
chotic medications and psychotherapy represents the best oppor-
tunity to retain long-term function in what will be essentially
a life-long disorder for many individuals (4). The earlier stages
of psychosis are also associated with the greatest risk of numer-
ous complications, such as social isolation, development of drug
use and criminality, and suicide (5). Importantly, patient and
family attitudes toward treatment may be most receptive in the
early phases of the illness (6). As a whole, research on the
effectiveness of EPI studies has indicated the key value of such
programs, demonstrating that patients whose psychosis remains
untreated for longer periods of time have a significantly poorer
long-term outcome, reflected in worse functional performance,
lower rates of remission, and decreased quality of life (7). EPI
programs have also been demonstrated to lead to better clin-
ical and functional outcomes than standard care programs for
extended periods of time (8–10), even after individuals have left
the program.
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THE VANCOUVER/RICHMOND EARLY PSYCHOSIS INTERVENTION
PROGRAM
The Vancouver/Richmond EPI program provides specialized sup-
port for patients and their families, who have recently experienced
issues with psychosis. The program covers a catchment area for
the cities of Vancouver and Richmond (combined population:
793,000) in the southwestern region of the province of British
Columbia, Canada, and is supported publically through the Van-
couver Coastal Health Authority – a government agency. The
program accepts patients between the ages of 13 and 30 with recent
onset symptoms of psychosis. Team members at the program
include psychiatrists (including those with specialized experience
in treating children and adolescents), psychiatric nurses, social
workers, child and family therapists, occupational therapists, and
case workers. The services that are available at the program include
individualized care in the following areas:
• Assessment
• Treatment
• Medication management
• Second opinions
• Consultations
• Case management
• Support and recovery
• Prevention of relapse
• Support returning to work or school
• Assistance to families to manage their family life in relation to
their family member
• Patient and family psychoeducation.
Referrals to the Vancouver/Richmond EPI program come from
a widespread number of different sources. These include the
regional health authority central intake lines, hospitals, primary
care physicians, secondary and post-secondary schools, and family
members or potential patients who have heard about the program
through community sources. A number of additional services have
been developed, which focus on maintaining the metabolic and
cardiovascular health of the patients (these are described in more
detail below). Furthermore, a number of ongoing research studies
at the program with a focus on the biological basis of metabolic
dysregulation in patients treated with antipsychotic drugs provide
additional opportunities for patients to learn about their physical
health.
CARDIOMETABOLIC HEALTH IN PATIENTS TREATED WITH
ANTIPSYCHOTIC DRUGS
It is now well known that individuals with a psychotic disorder who
are treated with an antipsychotic drug are significantly more likely
to exhibit poor metabolic and cardiovascular health compared
to the general population (11). Life expectancy may be reduced
by up to 25 years in patients with schizophrenia, which predom-
inantly reflects increased morbidity and mortality from causes
other than suicide, namely, type 2 diabetes mellitus (DM) and
cardiovascular disease (12). The factors that contribute to poor
health are those associated with an unhealthy lifestyle, including
a non-nutritious diet, lack of exercise, and high rates of smok-
ing (13–15). However, an additional factor that has been the
focus of considerable research over the past decade is the direct
cardiometabolic effects of the antipsychotic drugs themselves (16–
19). Antipsychotic drugs can be given for a wide range of different
psychiatric indications, in both adults and youth (20–23).
The second generation antipsychotic drugs (atypicals), in par-
ticular, have been associated with severe metabolic dysregulation.
These effects are so severe that the American Diabetes Association,
the American Psychiatric Association, the American Association
of Clinical Endocrinologists, and the North American Association
for the Study of Obesity co-sponsored a Joint Consensus State-
ment, providing guidelines for assessment of metabolic risk for all
patients being treated with atypical antipsychotic drugs (24).
Weight gain is the most commonly reported adverse effect
with the atypical antipsychotics, likely due to its prominence and
ease of measurement. Based on the National Cholesterol Educa-
tion Programs Adult Treatment Panel III, clinical definition of
the metabolic syndrome requires the presence of at least three
risk factors (25). Among patients with metabolic syndrome, the
relative risk for type 2 DM and coronary heart disease is 1.5–5
times that of the general population (26). Numerous studies have
reported high rates of metabolic syndrome in atypical treated
patients, with prevalence rates of over 50% for prediabetes or
type 2 DM in some adult psychiatric inpatient settings (27–29). In
the large head-to-head clinical trial of atypical antipsychotics, the
Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE)
Study (a major, multi-center trial sponsored by NIMH) observed
that 43% of patients treated with atypicals had metabolic syn-
drome. Controlling for BMI, CATIE men were 85%, and CATIE
women 137% more likely to have metabolic syndrome than non-
psychiatric subjects (30). Importantly, evidence indicates that
youth appear to be at higher risk than adults for antipsychotic-
induced weight gain and associated metabolic abnormalities (31–
33), emphasizing the need for close monitoring of patients in EPI
programs.
PROGRAMS TO IMPROVE CARDIOMETABOLIC HEALTH
A number of different programs have been implemented at
the Vancouver/Richmond EPI program with the specific goal of
improving the physical health of patients who are treated by the
multidisciplinary team at the site. Patients are made aware of these
programs as soon as their initial meeting with a psychiatrist. All
programs are completely voluntary and free of charge, although
all patients are strongly encouraged to take part in these optional
activities. Patients’ families are also provided with information
about these programs to help enlist their support in encouraging
patients to participate.
In these programs, patients routinely meet in a group format
to discuss strategies to learn about and improve their physical
health. When health-related goals are established, plans are struc-
tured according to the SMART criteria (i.e., goals must be Specific,
Measurable,Achievable,Realistic, and T ime related) (34). When-
ever possible, goals are set as precisely as possible. In setting a
precise goal, including dates, times, and amounts, it allows progress
to be measured and thus the patient has a clearer sense of whether
the exact goal has been achieved or they are at least making
advances. When there are several goals involved, the patient is
encouraged to set priorities. This can prevent the patient from
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feeling overwhelmed by having too many goals, and draws atten-
tion toward priorities. When setting goals, writing them down can
avoid confusion and lend them more force. It is also important
to keep operational goals small; if a goal is too large, progress can
appear difficult. Keeping goals modest and incremental provides
more opportunity for reward.
When initially setting goals, patients are encouraged to think a
goal through, with regard to the following questions:
• What skills do I need to achieve this?
• What information or knowledge do I need?
• What help, assistance, or collaboration do I need?
• What resources do I need?
• What can block my progress?
• Am I making any assumptions?
• Is there a better way of doing things?
After a goal has been set by the patient, they will complete a
Healthy Lifestyle Goal Development Worksheet. Although com-
pleted individually, these worksheets are reviewed as a group, and
a photocopy is placed in the patient’s medical chart.
METABOLIC MONITORING PROGRAM
A key protocol that is supported by the Vancouver/Richmond
EPI program is the Metabolic Monitoring Program. As noted
above, it is now recommended that all patients treated with atypi-
cal antipsychotic medications be screened routinely for metabolic
abnormalities after starting treatment (24). For a number of dif-
ferent reasons, including traditional boundary issues, psychiatrists
usually do not take direct anthropometric measurements of their
patients during clinical appointments. In an outpatient setting,
which represents the context of the typical EPI program (35),
patients will be seen separately by their primary care provider for
issues of general health, which may include cardiometabolic side
effects related to medications. However, this can create a discon-
nection between the primary health care provider and the patient’s
psychiatrist, and result in less thorough or frequent metabolic
screening (36, 37).
At the Vancouver/Richmond EPI program, a medical special-
ist trained in medical biochemistry with extensive experience in
treating endocrine issues related to cardiometabolic disorders runs
a clinic once per month. At that time, patients in the program are
encouraged to follow an established screening algorithm, which
monitors patients’ cardiometabolic health closely through the first
two years in the program. According to this algorithm, each patient
should be screened at baseline entry into the psychosis program
and 1, 2, 3, 6, 9, and 12 months, and then once per year afterward.
During the metabolic workup, the specialist obtains a compre-
hensive overview of the cardiometabolic health of the patient,
enabling an accurate estimation of overall health risk factors.
Indices measured include height and weight (BMI), waist circum-
ference (while ethnicity is also noted to account for differences in
risk based on ethnic background norms), resting blood pressure,
resting heart rate, fasting plasma glucose, fasting total cholesterol,
fasting LDL, fasting HDL, fasting triglycerides, and fasting insulin
levels for patients under 17 years old. These values are reviewed to
determine if criteria have been met for metabolic syndrome, and
then considered in combination with other risk factors such as
smoking status and current medications to determine the overall
health risk, and whether specific interventions may be necessary
(38, 39).
Interventions available include education of the patient about
the nature of metabolic risk for patients with psychosis who are
treated with antipsychotic drugs. The signs and symptoms of
type 2 DM and diabetic ketoacidosis may be reviewed explicitly,
and lifestyle management options are discussed in depth. Self-
management goals will be developed, where the patient is encour-
aged to reduce or quit smoking, improve eating habits, increase
physical activity, decrease the amount of time spent each day sit-
ting, and also improve stress management and sleep habits. Finally,
the medical specialist may prescribe medications to improve meta-
bolic health or provide a referral to another medical specialist or
general practitioner. Referrals are also made to smoking cessation
support programs, exercise programs, and dieticians.
HEALTH-RELATED RESEARCH AT THE VANCOUVER/
RICHMOND EARLY PSYCHOSIS INTERVENTION PROGRAM
As noted above, patients who have recently experienced the onset
of a psychotic disorder and begun treatment with antipsychotic
medications are at significantly increased risk of worsened car-
diometabolic health, and ultimately developing disorders such as
type 2 DM and cardiovascular disease, leading to premature death.
In most cases, the biological nature of the metabolic dysregula-
tion observed in patients treated with antipsychotic medications
is not well understood, as the mechanism by which antipsychotic
drugs cause glucose intolerance, insulin resistance, weight gain,
and hyperlipidemia remains under investigation (40). It is par-
ticularly important to study cardiometabolic changes in patients
who have recently experienced the full onset of their psychotic
disorder and begun drug treatment for several reasons. First, this
may be the period of most rapid physical change, particularly as
patients are starting from a healthier baseline and some may have
not yet reached full sexual maturity (33). Second, patients have
less of a “history” with previous antipsychotic medications, and
are less likely to be treated with multiple antipsychotic drugs or
additional classes of psychotherapeutic medications (20), mean-
ing that observed physical changes can be interpreted with greater
clarity. Finally, the greater receptivity of patients and family during
this phase of the illness (6) is conducive to engaging the patients
in the type of longitudinal research studies that will ultimately
be necessary for progress to be made in understanding these
issues.
At the Vancouver/Richmond EPI program, there are currently
multiple active research studies, which focus on understanding –
and ultimately improving – the cardiometabolic health of patients
with a psychotic disorder. In most cases, these studies represent
direct translational research from our basic laboratory studies,
which currently focus on understanding the biology (41–45) and
treatment (46–48) of antipsychotic drug-induced metabolic dys-
regulation. We briefly discuss several of these ongoing studies
below. All studies are conducted with full approval by the eth-
ical review board of the University of British Columbia and in
accordance with national guidelines for clinical trials, and have
been registered with www.clinicaltrials.gov.
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IS HEALTH COACHING EFFECTIVE FOR IMPROVING METABOLIC HEALTH
IN PEOPLE WITH PSYCHOTIC DISORDERS? (CLINICALTRIALS.GOV
IDENTIFIER NCT01752465)
Background
Integrative Health Coaching is a term used to describe an inclu-
sive approach to improve the health of patients at the individual
level. It requires the application of evidence-based health psychol-
ogy and coaching principles to assist clients to achieve positive
health outcomes through cognitive and behavior change. Health
Coaching is typically conducted in the context of disease preven-
tion and/or chronic condition self-management within public and
private sector health services. It is suitable for interdisciplinary
teams of health professionals within chronic disease prevention,
early intervention, rehabilitation, and other chronic condition self-
management programs. Studies have confirmed the value of this
approach, such as the Duke Integrative Medicine Study, which
began in 2002 with a study funded by the Centers for Medicare and
Medicaid. This randomized clinical trial found that health coach-
ing intervention significantly reduced the 10-year prospective risk
of coronary heart disease (49). Additionally, other research studies
have reported that health coaching can lead to greater weight loss
in subjects following pregnancy (50) and in subjects with glucose
intolerance (51) or Type 2 DM (52). The benefits of this type of
program in patients who have recently been diagnosed with a psy-
chotic disorder for the first time, such as schizophrenia, remain
unknown.
Hypothesis
Based on the proven value of Integrative Health Coaching Pro-
grams in improving the long-term health of patient populations
with regard to obesity, type 2 DM, and cardiovascular risk, we are
testing the following hypothesis: in a first-episode psychosis pop-
ulation that has recently begun treatment with atypical antipsy-
chotic drugs, the inclusion of an Integrative Health Coaching
goal-setting model will significantly improve metabolic health
outcomes compared to usual treatment.
Protocol
We are conducting a non-blinded clinical trial of the efficacy of
Integrative Health Coaching techniques in 40 subjects who are
currently treated at the Vancouver/Richmond EPI program. All
subjects are randomly assigned to one of two treatment groups
(n= 20 subjects per group). In the first group, subjects receive
treatment for psychosis based on the current standard of care,
which includes psychosocial training (social skills training, cog-
nitive therapy, stress reduction training, and vocational rehabil-
itation), education, and pharmacological treatment. The second
group of subjects receives not only the standard of care treatment
for psychosis but also additional Integrative Health Coaching to
improve physical health (see below). For inclusion in the study,
subjects must be prescribed an atypical antipsychotic drug. Intake
into the study is naturalistic, as the subject’s psychiatrist at the
early psychosis program is free to prescribe whatever psychotropic
medication they decide is best for the subject. Subjects in both
treatment groups are given assessments of physical health, with a
particular emphasis on metabolic dysregulation, at months 1, 2, 3,
and 6 from when they enter the study. Subjects are characterized
with clinical data on demographics, health history, prior and con-
comitant medications, and metabolic indices (e.g., height, weight,
waist circumference, resting blood pressure and heart rate, fasting
plasma glucose, total cholesterol, LDL-C, HDL-C, triglycerides,
insulin, etc.). This information is collected via chart review. Diag-
noses are abstracted from reports and notes written by physicians
and case managers at Vancouver Richmond EPI. This includes
the clinical diagnoses at intake and, if applicable, any changes in
clinical diagnosis at the time of discharge, as well as descriptions
of positive and negative symptoms, abnormalities in affect, prob-
lems in social and occupational functioning, and any cognitive
problems. Data are collected and analyzed for differences between
the two groups at the end of the study. Results will be analyzed
based on intent-to-treat analysis, and comparison of metabolic
and other health indices compared between the two groups using
t-test and chi-square analyses. Based on prior studies using Inte-
grative Health Coaching techniques and the reported effect sizes,
we determined that the present study with 40 subjects will have
80% power to detect a true treatment difference in the change of
metabolic improvement of 0.5 SD. For example, behavioral health
coaching in patients with type 2 DM has been shown to exert effect
sizes as large as Cohen’s d = 1.50 on behavioral measures, although
physiological changes may be lower (53).
Self-management techniques are utilized to facilitate patient
engagement in their own health care, including participating in
lifestyle activities that protect and promote physical health, learn-
ing to monitor and manage symptoms and signs of metabolic
dysregulation, and learning to manage the impact of metabolic
side effects on functioning, while strongly promoting adherence
to current treatment regimens. Training identifies the patient as an
expert in their own health recovery and supports the individual to
find their own solutions to problems, based on the use of intrin-
sic motivators. Subjects identify specific, individualized goals with
positive imagery, and are trained to overcome barriers to change.
For example, rather than simply state “I want to lose 10 kg,” the
subject will be coached to develop specific goals and action plans,
such as committing to walking three times per week for 30 min
on Mon–Wed–Fri and replacing take-away foods for dinner with
healthy home cooked meals three times per week. Subjects receive
1 h of Health Coaching twice monthly during the first 3 months
of the study, and then monthly for the remaining 3 months.
Outcome measures
We use routine measures of metabolic health, which are used for
all patients who enter the EPI program. We record all of the indices
that are required to make an evaluation of metabolic syndrome.
It includes information on obesity (BMI, waist circumference),
blood pressure, fasting plasma glucose, fasting cholesterol (LDL
and HDL),and fasting triglycerides. We also measure liver function
(AST and ALT) as well as other relevant metabolic parameters. We
also ask subjects to complete self-report scales of the Short Form-
36 instrument, which is a well-established tool to measure health
and well-being in psychiatric patients (54). Subjects also complete
the Three-Factor Eating Questionnaire, which is a validated tool
comprising 51 items that measure three components of eating
behavior (55). Factor I reflects conscious mechanisms for limiting
food intake, factor II reflects a variety of disinhibition behaviors,
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while factor III reflects feelings of hunger and its behavioral con-
sequences. Psychotropic medication prescription information is
obtained from medical charts, while each subject is asked about
their medication adherence using a standardized questionnaire.
Anticipated results
We predict that subjects who only receive the standard of care
treatment will exhibit worse metabolic outcome measures over the
duration of the 6 months, compared to baseline, as the metabolic
effects of antipsychotic medications become greater over time. In
contrast, we predict that metabolic indices will show significantly
less development in subjects receiving Health Coaching. This latter
group will also show better general health, well-being, better eating
behaviors, and stronger medication adherence. If our hypothesis
is proven to be correct, then we will have demonstrated for the
first time in a population with psychosis that Integrative Health
Coaching can significantly improve metabolic and general health.
This will improve morbidity, long-term mortality, and quality of
life in patients, and may represent a considerable cost savings to
the health care system using a set of techniques that are relatively
inexpensive and easy to implement.
A COMPARISON OF ARIPIPRAZOLE VERSUS HIGHER METABOLIC RISK
ANTIPSYCHOTIC DRUGS ON ADIPOSITY USING MRI (CALM)
(CLINICALTRIALS.GOV IDENTIFIER NCT01739127)
Background
Evidence indicates that patients who have just started treatment
with antipsychotic drugs are at higher risk for antipsychotic-
induced weight gain and associated metabolic abnormalities than
older patients (31). A recent meta-analysis indicated that switch-
ing from other atypical antipsychotics to the antipsychotic drug
aripiprazole resulted in significant weight loss and may be an opti-
mal treatment for patients who exhibit drug-induced weight gain
(56). Weight gain is a common adverse effect with most of the
atypical and some of the typical antipsychotic drugs. Tandon and
Halbreich reviewed the relative propensity of all atypical antipsy-
chotic drugs to induce weight gain in adults (57), and expressed
the order as follows: clozapine> olanzapine> risperidone=
quetiapine> ziprasidone= aripiprazole. It is important, though,
to note that weight gain per se is not necessarily a strong predictor
of subsequent metabolic and cardiovascular complications. Evi-
dence from the extensive diabetes literature indicates that there are
major differences between intra-abdominal visceral fat (defined
as fat accumulation around the viscera and intra-abdominal solid
organs) versus peripheral/subcutaneous fat in the pathogenesis
of metabolic syndrome. Visceral fat is a highly active endocrine
organ, and levels of visceral fat are a much stronger predictor
of mortality than other types of body fat (58). The overwhelm-
ing majority of studies have demonstrated that when compared
directly, levels of visceral fat are a much better predictor of insulin
resistance and hyperglycemia (two of the core symptoms of type
2 DM) than levels of subcutaneous fat (59, 60). For example,
Usui and colleagues reported in 2010 that levels of visceral fat
were four times more accurate than levels of subcutaneous fat in
predicting insulin resistance (61). Despite their widespread use,
anthropometric measures of adiposity, such as BMI and waist
circumference, have been subject to criticism by experts (62).
Importantly, several recent studies have reported that intrahepatic
lipid levels are at least as accurate a predictor of glucose intol-
erance as levels of visceral fat (63–65). Hepatic steatosis, or “fatty
liver,” is a well-known pathological marker of numerous metabolic
disorders.
While visceral fat and intrahepatic lipids are, therefore, a more
accurate predictor of metabolic dysregulation and potential car-
diovascular complications, these indices are not readily acquired.
Indirect measures of adiposity, such as measurement of waist cir-
cumference and BMI, are cheap and convenient techniques, but
they do not provide accurate quantitative assessment of abdom-
inal visceral fat, or regional distribution in and around specific
organs, such as the liver. This is a critical shortcoming, for reasons
described above, as well as because there are major gender differ-
ences in the accumulation and amount of visceral fat that cannot
be controlled for based on peripheral measures.
The “gold standard” technique of fat measurement, there-
fore, has been magnetic resonance imaging (MRI), which enables
both the amount and regional distribution of visceral fat to be
determined non-invasively. This technique is considerably more
accurate than dual X-ray absorptiometry (DEXA) and does not
expose subjects to the potentially harmful effects of radiation
associated with DEXA or CT scans. To date, there has been only
one study that reported the effects of antipsychotic drugs on
visceral fat deposition using MRI (66). This study, in Chinese
Han adults, showed a marked increase in visceral fat – which
was significantly greater than changes in subcutaneous fat – after
10 weeks of treatment with either risperidone or chlorpromazine,
assessed using a low-field-strength scanner (0.2 T). There has never
been a study of the effects of antipsychotic drugs on intrahepatic
lipid levels, which is assessed using magnetic resonance spec-
troscopy (MRS). The effects not only of aripiprazole but also all
other antipsychotics on visceral fat accumulation and intrahep-
atic lipid levels in adolescents remain completely unknown. The
goal of the current study is to study aripiprazole in the first ever
study of antipsychotic-induced weight gain on levels and regional
distribution of visceral versus subcutaneous fat in EPI patients
using MRI.
Hypotheses
1. Patients treated with a lower metabolic risk antipsychotic drug
(aripiprazole) will exhibit no significant difference in metabolic
indices, including MRI/MRS measures, compared to control
subjects at either the beginning of the study or after 16 weeks
of drug treatment.
2. By contrast, patients treated with antipsychotic drugs that rep-
resent a higher metabolic risk (risperidone, quetiapine, or
olanzapine) will exhibit significant metabolic changes, such
as increased visceral fat and greater lipid infiltration of the
liver, compared to vehicle and aripiprazole-treated patients.
This effect will be modest at the time of the initial scan, and
substantially greater at the time of the second scan.
3. The significant increase in the amount of visceral fat and lipid
infiltration of the liver following antipsychotic drug treatment
with the higher risk drugs will correlate strongly with metabolic
dysregulation, such as higher fasting glucose levels and insulin
resistance.
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Protocol
Design: The study is a longitudinal, naturalistic intake study. We
are recruiting 90 subjects, who are interviewed and receive MRI
scans on entry into the study and again after 16 weeks. Of these,
30 are age- and gender-matched healthy subjects who serve as
controls. For the remaining 60 subjects treated with antipsychotic
drugs, there are two treatment groups, based on the metabolic
liability of the antipsychotic drugs they are treated with. We are
recruiting 30 subjects treated with aripiprazole, which represents
the low-risk group, and 30 subjects treated with higher metabolic
risk drugs (risperidone, quetiapine, and olanzapine). Groups are
matched on sex and age. At entry into the study, subjects receive an
abdominal MRI/MRS scan to measure fat and lipid composition
of the liver. Metabolic tests to complement the fat imaging are also
performed to gather an independent index of glucose intolerance
and insulin resistance.
Subjects must have received no more than 6 months lifetime
total of prior treatment with antipsychotic drugs. Anthropometric
measures, which include height, weight, and waist circumferences,
as well as laboratory evaluations performed in the fasting state, are
obtained. To assess glucose intolerance, we conduct an oral glucose
tolerance test (1.75 g/kg of glucola with maximum dose of 75 g
administered following a 12 h fast). Height, weight, blood pres-
sure, pulse, and waist circumference are obtained on the day of the
oral glucose tolerance test. Fasting lipid profile (total cholesterol,
triglycerides, LDL-C, HDL-C), leptin, adiponectin, and proinsulin
are also measured. Antipsychotic drug levels are measured by
HPLC to ensure medication adherence.
Clinical measures include:
i. Positive and negative syndromes scale (PANSS)
ii. Calgary depression scale (CDS)
iii. Mini-international neuropsychiatric interview (MINI v6.0)
iv. Social and occupational functioning scale (SOFAS)
v. Anthropomorphic assessments for basal metabolic index
(height, weight, BMI, blood pressure, pulse, waist circumfer-
ence).
After laboratory and cognitive tests have been completed, sub-
jects complete an abdominal scan with the MRI scanner at UBC
Hospital. Image acquisition are performed on a 3-T clinical MRI
scanner (Philips System), using a body coil and a T1 weighted
acquisition of 200 contiguous 1 mm axial slices of the abdomen,
between the lower rib margin and the iliac crest. Scan time is
45 min (plus approximately 10 min extra time in the scanner for
alignment). Total visceral fat, subcutaneous fat, and intramuscular
fat are segmented automatically (see Figure 1); regional distribu-
tion of fat is determined by manual segmentation. MRS quantifies
lipid peaks to measure lipid content of a liver-based voxel (scan
time= 15 min). All subjects are followed up 16 weeks later for a
second interview and MRI/MRS scan. Drug adherence is assessed
using techniques that we have used previously. Data are analyzed
using an “intent-to-treat” statistical approach. In addition to the
main intent-to-treat analysis, we will conduct a secondary “com-
pleters” analysis with only subjects who did not switch from one
class of antipsychotic drugs to the other. Group sizes are suffi-
ciently powered to detect significant differences, based on power
FIGURE 1 | (A) Representative MRI image (axial plane) performed on a 3-T
clinical scanner. (B)Total visceral fat (yellow), subcutaneous fat (blue), and
intramuscular fat (orange) manually segmented.
calculations and our prior observations. Linear regression analysis
will be performed to determine the relationship between visceral
or subcutaneous fat and liver lipids versus metabolic changes.
Anticipated significance
The present study will be the first ever to use MRI to assess the
effects of atypical antipsychotic drugs on levels of visceral and sub-
cutaneous fat, as well as lipid infiltration of the liver, in patients
recently starting antipsychotic drugs. It will also be unique in that
it will employ these procedures to compare the metabolic side
effects of atypical drugs with low versus higher metabolic side
effect risks. The results of this study could provide important
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information about the potential hidden harmful effects associated
with atypical drug use for atypicals, as there is little knowledge
about the effects of these pharmacotherapies on visceral fat accu-
mulation in patients. The data accumulated may ultimately be
useful for the development of treatment guidelines. Clear evidence
of increased adiposity in higher metabolic risk antipsychotic drug-
treated patients could provide strong impetus for prescribers to
use low metabolic risk drugs to improve cardiometabolic health
in patients with psychosis.
ADVERSE EVENTS AND GENOMICS IN SCHIZOPHRENIA (AEGIS)
(CLINICALTRIALS.GOV IDENTIFIER NCT01966588)
Background
As noted above, many of the atypical antipsychotic drugs com-
monly cause serious metabolic disturbances, including weight
gain, hyperlipidemia, glucose intolerance, and insulin resistance,
resulting in higher rates of cardiometabolic disorders. Extensive
research has shown that specific antipsychotic drugs or com-
binations thereof may provide a differential risk for metabolic
dysregulation in patients. There are large inter-individual differ-
ences in vulnerability to antipsychotic drug-induced side effects.
An emerging body of evidence in the field of pharmacogenomics
indicates that these inter-individual differences may be due in
significant part to genetic factors, either as inherited or de novo
genetic variation (67, 68). However, the key genes or biological tar-
gets involved remain largely unknown, due to the complexity of the
clinical picture, where diverse factors such as activity levels, hunger,
diet, substance use, concurrent medications, and choice of antipsy-
chotic drug can all influence the risk for metabolic dysregulation.
Furthermore, few comprehensive genetic studies have addressed
this question, and those that have been performed have either used
a candidate gene approach or have assessed only common variants.
Comprehensive, high-resolution pharmacogenomic studies are
challenging, but would benefit greatly from a study that recruited a
homogeneous population treated with antipsychotics, and one in
which metabolic effects are not obfuscated by exposure to previous
medications. A key advantage of conducting the present study at
the Vancouver/Richmond EPI program is that it is the only one in
British Columbia to have implemented a metabolic screening pro-
gram, where detailed information is available about the metabolic
health of patients from the time that they entered the program.
Using genetic information to predict drug responses would allow
a greater number of patients to benefit from the use of antipsy-
chotic drugs with personalized assessments of therapeutic efficacy
and side effect profiles (69).
Hypothesis
Genetic variants will be identified that predict metabolic responses
to antipsychotic drugs. The whole exome analysis will detect vari-
ations governing metabolic dysregulation in key physiological
pathways known a priori to regulate metabolism.
Protocol
We are conducting a multi-year study to obtain the genomic
DNA from approximately 200 patients registered with the Vancou-
ver/Richmond EPI program. Intake is naturalistic, as we recruit
all potential patients who are currently being treated with an
antipsychotic. All subjects who take part in this study are asked
to have their medical charts reviewed for clinical data (especially
clinical blood work results), which includes current medications,
pre-existing metabolic risks (e.g., smoking, obesity, etc.), height,
weight, waist circumference, blood pressure, heart rate, and fast-
ing metabolic indices (plasma glucose, insulin, triglycerides, and
cholesterol). General clinical data on demographics, health his-
tory, prior and concomitant medications, and any other metabolic
indices are also collected from the medical charts (the metabolic
indices are the same as in the IHC trial). Any current medical
problems experienced in the last 3 days in the form of antipsy-
chotic medication side effects will be captured with the Udvalg for
Kliniske Undersøgelser (UKU) Side Effect Rating Scale. Similar
to the IHC trial, information on diagnoses in patients participat-
ing in this trial will include the clinical diagnoses, and descrip-
tions of positive and negative symptoms, affect abnormalities,
problems in social and occupational functioning, and cognitive
problems. To accurately phenotype this patient population in rela-
tion to antipsychotic-induced metabolic dysfunction, the 48-item
UKU is conducted on all subjects to produce a comprehensive
measure of the severity and frequency of psychic, neurological,
autonomic, and other side effects induced by antipsychotic drugs.
This assessment is accomplished by a semistructured interview
with each patient during which the scale is gone through point by
point and is supplemented by clinical observation and informa-
tion obtained from the case records or clinical staff. Medication
adherence is assessed using the Medication Adherence Rating
Scale.
All subjects are then asked to provide a blood sample for
whole-exome sequencing. To obtain the genomic DNA samples,
subjects have a total of 22 ml (5.5 teaspoons of venous blood)
withdrawn from their arm. Samples will be collected by a cer-
tified phlebotomist using approved protocols. Venous blood is
extracted from the median cubital vein in the cubital fossa of
the arm. Samples are collected directly into two PAXGene col-
lection tubes and may be stored for many years in a Biobank.
The blood draw is performed at one time point only and takes
place wherever the subject receives medical care. Genomic DNA
is isolated and purified using the QIAGEN blood mini kit for
DNA. Purified genomic DNA is split into aliquots with one aliquot
being used for exome library preparation using the Nextera Rapid
Capture Exome kit, which requires only 4 Gb of sequence, with
greater read depths possible if needed. Enriched exomes are mol-
ecularly barcoded such that multiple exomes can be sequenced
simultaneously.
High-throughput sequencing is performed at the UBC Phar-
maceutical Sciences Sequencing Center (PSSC). Illumina® hiSeq
2500 instrument and a minimum of 20 million sequence reads
are captured for each DNA sample using a 2× 100 paired-end
sequencing protocol. We empirically test the read-depth/coverage
relationship by sequencing several samples to a 3× greater depth
and then undersample the data bioinformatically. Raw data in the
form of .bcl files are converted to fastq and the reads mapped using
the GATK platform established by the Broad Institute. Samples are
tracked by the PSSC’s Laboratory Information Management Sys-
tem by unique identifiers only. Mapped sequences associated with
each identifier are stored on the local network for analysis.
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Significance
Based on the highly detailed metabolic phenotype we will mea-
sure, we anticipate that the genomic findings from the current
proposal will provide important novel targets to help us under-
stand the metabolic side effects of antipsychotic drugs, either in
terms of predicting which drugs may be better or worse for spe-
cific individuals, or indicating potential physiological pathways to
study for future drug development. We will then hopefully be able
to integrate such findings into our active preclinical and clinical
programs.
CONCLUDING REMARKS
The beneficial effects of EPI programs on mental health and
functional outcome are now well established in patients with a
psychotic disorder. However, the long-term physical health of indi-
viduals who are treated with antipsychotic medications should
remain a priority, given their increased risk for cardiometabolic
disorders. The Vancouver/Richmond EPI program has been at the
forefront of this challenge. The multidisciplinary team is commit-
ted to improving lifelong physical health by a number of important
programs that involve working with and educating patients and
their families about health issues, while also ensuring regular meta-
bolic monitoring by expert medical staff. This strong focus on
improving physical health has created an excellent environment
for conducting high quality and “cutting edge” research, whereby
patients become more empowered to learn about their own physi-
cal health, and also be a part of clinical research that may ultimately
improve the physical health of many others.
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